UNITY Biotechnology, Inc. to Participate in the H.C. Wainwright Ophthalmology Virtual Conference
August 16 2021 - 4:03PM
UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology
company developing therapeutics to slow, halt, or reverse diseases
of aging, today announced that members of its senior management
team will present at the upcoming H.C. Wainwright Ophthalmology
Virtual Conference.
H.C. Wainwright Ophthalmology Virtual
ConferenceDate: Tuesday, August 17, 2021 On-Demand
Presentation Available: 7:00 a.m. ET
As part of the event Anirvan Ghosh, Ph.D., chief
executive officer of UNITY, will participate in the panel titled,
“Vision Repair Beyond Traditional Anti-VEGF Therapy – What Does the
Future Hold?” hosted by Matthew Caufield, equity research analyst
at H.C. Wainwright. To register for the event, please visit the
conference website here.
A live audio webcast of the corporate presentation will be
available through the Investors & Media section of UNITY’s
website here. An archived replay will be available for 90 days
following the event.
About UNITY UNITY is
developing a new class of therapeutics to slow, halt, or reverse
diseases of aging. UNITY’s current focus is on creating medicines
to selectively eliminate or modulate senescent cells and thereby
provide transformative benefit
in age-related ophthalmologic and neurologic diseases.
More information is available
at www.unitybiotechnology.com or follow us
on Twitter and LinkedIn.
Forward-Looking
Statements This press release contains
forward-looking statements including statements related to UNITY’s
understanding of cellular senescence and the role it plays in
diseases of aging, the potential for UNITY to develop therapeutics
to slow, halt, or reverse diseases of aging, including for
ophthalmologic and neurologic diseases, our expectations regarding
potential benefits, activity, effectiveness, and safety of UBX1325,
the potential for UNITY to successfully commence and complete
clinical studies of UBX1325 for DME, AMD, and other ophthalmologic
diseases, the expected timing of results of our studies of UBX1325,
the timing of the expected commencement, progression, and
conclusion of our studies including those of UBX1325, and UNITY’s
expectations regarding the sufficiency of its cash runway. These
statements involve substantial known and unknown risks,
uncertainties, and other factors that may cause our actual results,
levels of activity, performance, or achievements to be materially
different from the information expressed or implied by these
forward-looking statements, including the risk that
the COVID-19 worldwide pandemic may continue to
negatively impact the development of preclinical and clinical drug
candidates, including delaying or disrupting the enrollment of
patients in clinical trials, risks relating to the uncertainties
inherent in the drug development process, and risks relating to
UNITY’s understanding of senescence biology. We may not actually
achieve the plans, intentions, or expectations disclosed in our
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual results or events could
differ materially from the plans, intentions, and expectations
disclosed in the forward-looking statements we make. The
forward-looking statements in this press release represent our
views as of the date of this release. We anticipate that subsequent
events and developments will cause our views to change. However,
while we may elect to update these forward-looking statements at
some point in the future, we have no current intention of doing so
except to the extent required by applicable law. You should,
therefore, not rely on these forward-looking statements as
representing our views as of any date subsequent to the date of
this release. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of UNITY in general, see UNITY’s most
recent Quarterly Report on Form 10-Q for the quarter
ended June 30, 2021, filed with the Securities and
Exchange Commission on August 10, 2021, as well as other
documents that may be filed by UNITY from time to time with
the Securities and Exchange Commission.
Media
Canale Communications
Jason Spark
jason.spark@canalecomm.com
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Aug 2024 to Sep 2024
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Sep 2023 to Sep 2024